Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fsd Pharma Inc Cl B (NQ: HUGE )

0.1529 -0.0091 (-5.62%)
Streaming Delayed Price Updated: 1:55 PM EDT, Jul 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fsd Pharma Inc Cl B

< Previous 1 2 3 Next >
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
Promising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing Completed
FSD Pharma Inc. (NASDAQ: HUGE), a biopharma company developing innovative assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, announced the first... 
Via Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
Lawsuit: GBB Drink Lab Seeks $53M From FSD Pharma For Nondisclosure Contract Breach & Trade Secret Misappropriation
GBB Drink Lab, which makes the world’s first formulated drink that aids in rapid blood alcohol detoxification - a handy tool, has filed a lawsuit against the psychedelics biotech company FSD Pharma... 
Via Benzinga
FSD Pharma Shares Slightly Up On Agreement To Sell Cannabis Facility For $12.9M
FSD Pharma Inc. (NASDAQ:HUGE) (CSE: 
Via Benzinga
GBB Drink Lab Files $53M Lawsuit Against FSD Pharma for Nondisclosure Contract Breach and Trade Secret Misappropriation
GBB Drink Lab Files $53M Lawsuit Against FSD Pharma for Nondisclosure Contract Breach and Trade Secret Misappropriation 
Via News Direct
Topics Lawsuit
Exposures Financial Legal
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
GBB Drink Lab Sends a Cease-and-Desist Demand
FSD Pharma Breached NDA with GBB After GBB Terminates Acquisition Discussions 
Via News Direct
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules 
Via Benzinga
Novel Compound Begins Clinical Testing For Potential Treatment Of Multiple Sclerosis
FSD Pharma Inc. (NASDAQ: HUGE) has dosed the first subjects in its first clinical trial assessing the New Chemical Entity (NCE) Lucid-21-302, or Lucid-MS, targetting multiple sclerosis. 
Via Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space. 
Via Benzinga
FSD Pharma To Spin Out New Publicly Trading Subsidiary As Distribution To Shareholders
Psychedelics biotech company FSD Pharma Inc. 
Via Benzinga
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses 
Via Benzinga
FSD Pharma's Australian Entity To Proceed With Phase I Trial For Major Depressive Disorder
Biotech company FSD Pharma Inc. (NASDAQ: HUGE)’s Australian business FSD Pharma Australia Pty Ltd. has been approved by the Alfred Ethics Committee to begin a Phase 1 clinical trial of next-gen drug... 
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
Psychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its Stock
FSD Pharma Inc. (NASDAQ: HUGE) has renewed a service agreement with shareholder intelligence services provider ShareIntel LLC to assist in ongoing 
Via Benzinga
Benzinga's Psychedelics Capital Conference: Meet An Unrivaled Group Of Advisors And Fund Partners
The upcoming Psychedelics Capital Conference constitutes Benzinga’s effort to provide an exclusive opportunity to meet, connect with and learn from some of the most knowledgeable people in the space. 
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
Shark Tank's Kevin Harrington Will Provide Strategic Guidance To Major Psychedelics Company
Psychedelics biopharma company FSD Pharma Inc. (NASDAQ: HUGE)’s advisory board has a new member: the iconic entrepreneur and inventor of the infomercial Kevin Harrington. 
Via Benzinga
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Awakn Opens Fourth European Clinic, Norway Takes Center Stage 
Via Benzinga
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space. 
Via Benzinga
FSD Pharma Closes CA$16.4M Sale Of Ontario Cannabis Processing Facility, Here's What's Next
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) has closed the sale of the company’s former cannabis processing facility located in Cobourg, Ontario, Canada, for gross proceeds of CA$16.4... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 61 companies hit new 52-week lows. 
Via Benzinga
Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions. 
Via Benzinga
FSD Pharma Enters Agreement With Tekkfund Capital Corp To Develop Business
FSD Pharma Inc. (NASDAQ: HUGE) entered into an agreement with Tekkfund Capital Corp to structure and assist “with certain business development strategies.” 
Via Benzinga
64 Biggest Movers From Friday
Gainers Clever Leaves Holdings Inc. (NASDAQ: CLVR) shares surged 143% to settle at $3.84 on Friday after the company reported better-than-expected Q4 sales results and reaffirmed... 
Via Benzinga
Cannabis Stocks That Moved On News That Federal Cannabis Legalization Bill Heads To House For Vote Next Week
The House of Representatives intends to vote on a bill to federally legalize cannabis for the second time in history next week, congressi... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 71 stocks hit new 52-week lows. Noteable 52-Week Lows: 3M (NYSE:MMM) was the biggest company in terms of market cap to set a new 52-week low. OceanPal (... 
Via Benzinga
93 Biggest Movers From Friday
Gainers Inspirato Incorporated (NASDAQ: ISPO) shares surged 50.5% to close at $54.90. Guardforce AI Co., Limited (NASDAQ: GFAI) jumped 45.4% to settle at $0.5979 on Friday. EF... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.